

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)



(10) International Publication Number
WO 2020/196665 A1

(51) International Patent Classification:

A61K 31/44 (2006.01) *A61K 31/513* (2006.01)
A61K 45/06 (2006.01) *A61K 31/635* (2006.01)
A61K 31/4184 (2006.01) *A61K 31/517* (2006.01)
A61K 31/175 (2006.01) *A61K 31/519* (2006.01)
A61K 31/255 (2006.01) *A61K 31/4439* (2006.01)
A61K 31/675 (2006.01) *A61K 31/5377* (2006.01)
A61K 31/198 (2006.01) *A61K 31/47* (2006.01)
A61K 31/7008 (2006.01) *A61K 31/506* (2006.01)
A61K 31/706 (2006.01) *A61K 39/395* (2006.01)
A61K 31/7068 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/JP2020/013454

(22) International Filing Date:

25 March 2020 (25.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2019-057029 25 March 2019 (25.03.2019) JP

(71) Applicant: **OTSUKA PHARMACEUTICAL CO., LTD.**
[JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo,
1018535 (JP).

(72) Inventors: **OHI, Naoto**; c/o Otsuka Pharmaceutical Co.,
Ltd., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021
(JP). **OKUNO, Mitsuhiro**; c/o Otsuka Pharmaceutical Co.,
Ltd., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021
(JP). **TANAKA, Hideo**; c/o Otsuka Pharmaceutical Co.,
Ltd., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021
(JP).

(74) Agent: **SAEGUSA & PARTNERS**; Kitahama Konishi
Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka,
5410045 (JP).


(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ANTITUMOR COMPOSITION



(1)

(57) Abstract: An object is to provide a novel combination of antitumor agents that can significantly shrink tumors by synergistic antitumor action without increasing side effects as much as possible. Provided is an antitumor composition comprising the following compound (B) or a salt thereof for use in combination with the following antitumor agent (A): (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) a compound or a salt thereof represented by the following formula (1): wherein R^1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group optionally substituted with one or more halogen atoms; R^2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group; and m represents an integer of 1 to 3, provided that when m represents 2 or 3, R^1 is the same or different.



WO 2020/196665 A1